Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics, MD Anderson Ink Sponsored Research Agreement

NEW YORK (GenomeWeb) – Molecular diagnostics firm Signal Genetics and the University of Texas MD Anderson Cancer Center have announced an agreement to evaluate the clinical utility of Signal's MyPRS test for symptomatic multiple myeloma risk.

The microarray-based MyPRS test identifies patients with asymptomatic monoclonal gammopathies, including smoldering multiple myeloma and MGUS, with a high or low risk for rapid progression to symptomatic multiple myeloma.

Under the terms of the agreement, the partners will conduct a prospective 200-patient study led by MD Anderson researchers Elisabet Manasanch, Jatin Shah, Donna Weber, and Robert Orlowski. Signal will perform MyPRS testing on patient samples. The partners will also collect next-generation sequencing data to find new genetic information that could be used to characterize patients within the constellation of diseases. Patient enrollment has opened and work will begin this month, the partners said in a statement.

Financial and other details of the agreement were not disclosed.

"Stratifying patients into risk categories is a crucial step in determining the proper course of treatment, and MyPRS has the ability to provide physicians with this vital information," Signal Genetics President and CEO Samuel Riccitelli said in a statement. "We believe this study will provide additional support for the clinical utility of our assay."

The deal follows a similar arrangement Signal made with Moffitt Cancer Center in September 2015. In February 2015, the US Food and Drug Administration granted Signal conditional approval to use the MyPRS test as early entry criteria for a clinical trial to treat high-risk multiple myeloma. 

The Carlsbad, California-based firm also has a Little Rock, Arkansas-based CAP-accredited laboratory.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.